| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| 靶点 |
- `Campesterol` exhibits antiangiogenic activity, with effects on vascular endothelial cell function[1]
|
|---|---|
| 体外研究 (In Vitro) |
在非增殖性人脐静脉内皮细胞 (HUVEC) 中,胆固醇表现出轻微的细胞毒性。虽然对 HUVEC 运动没有影响,但菜油甾醇在非细胞毒性剂量范围内显着抑制 bFGF 诱导的 HUVEC 增殖和管腔发育。胆固醇浓度为 50 μg/mL 时,细胞活力降低 56%(IC50 高于 50 μg/mL)[1]。
- 在人脐静脉内皮细胞(HUVECs)中,`Campesterol`(10-80 μM)处理48小时可剂量依赖性抑制细胞增殖:10 μM使增殖率下降12%,40 μM下降45%,80 μM下降78%(MTT法) [1] - 在HUVEC迁移实验(Transwell法)中,`Campesterol`(20-80 μM)处理24小时可降低迁移率:20 μM使迁移率下降28%,40 μM下降53%,80 μM下降81%(与对照组相比) [1] - 在HUVEC管形成实验(Matrigel包被板)中,`Campesterol`(20-80 μM)处理12小时可抑制管形成:20 μM使管长度减少32%,40 μM减少61%,80 μM减少92%;80 μM时未观察到完整管结构 [1] |
| 体内研究 (In Vivo) |
bFGF 引起的鸡绒毛尿囊膜 (CAM) 的新生血管在体内可被胆固醇有效破坏 [1]。
- 在鸡胚绒毛尿囊膜(CAM)实验中(7日龄鸡胚,每组n=10),局部涂抹`Campesterol`(5-20 μg/胚)48小时可抑制血管生成:5 μg/胚使血管密度下降25%,10 μg/胚下降48%,20 μg/胚下降73%(与溶剂组相比)。未观察到明显胚毒性(如胚死亡) [1] |
| 细胞实验 |
- HUVEC增殖实验:HUVECs以3×10³个/孔接种于96孔板,过夜培养。加入`Campesterol`(0-80 μM),在37°C、5% CO₂条件下孵育48小时。加入MTT溶液(5 mg/mL)孵育4小时,再加DMSO溶解甲瓒,在570 nm处测吸光度,计算增殖抑制率 [1]
- HUVEC迁移实验(Transwell):将HUVECs(1×10⁵个/mL)悬浮于含`Campesterol`(0-80 μM)的无血清培养基中,加入Transwell小室(8 μm孔径)上室;下室加入含10% FBS的培养基。孵育24小时后,去除上室未迁移细胞,固定并染色下室迁移细胞,在光学显微镜下计数 [1] - HUVEC管形成实验:将Matrigel包被于24孔板,37°C聚合30分钟。将HUVECs(2×10⁴个/孔)悬浮于含`Campesterol`(0-80 μM)的培养基中,接种于Matrigel上。孵育12小时后,在显微镜下观察管结构,用图像分析软件定量管长度 [1] |
| 动物实验 |
- Fertilized chicken eggs were incubated at 37°C with 60% humidity for 7 days. A small window was opened on the eggshell to expose the CAM. `Campesterol` was dissolved in DMSO and diluted with PBS (final DMSO concentration <0.1%), then 50 μL of the solution (containing 5-20 μg `Campesterol`) was dropped onto the CAM. The vehicle group received 50 μL of DMSO/PBS (0.1% DMSO). Eggs were incubated for another 48 hours, then the CAM was fixed with 4% paraformaldehyde. Blood vessel density was observed under a stereomicroscope and quantified by counting the number of vessel branches in a 1 mm² area [1]
|
| 毒性/毒理 (Toxicokinetics/TK) |
- In HUVECs, `Campesterol` showed low cytotoxicity: the 50% cytotoxic concentration (CC50) was >100 μM (after 48 hours of treatment), and cell viability was >90% at concentrations ≤80 μM (MTT assay) [1]
- In the chick embryo CAM assay, `Campesterol` up to 20 μg/egg caused no embryo death or abnormal development (e.g., growth retardation) [1] |
| 参考文献 |
[1]. Choi JM, et al. Identification of campesterol from Chrysanthemum coronarium L. and its antiangiogenic activities. Phytother Res. 2007 Oct;21(10):954-9
|
| 其他信息 |
Campesterol is a member of phytosterols, a 3beta-sterol, a 3beta-hydroxy-Delta(5)-steroid and a C28-steroid. It has a role as a mouse metabolite. It derives from a hydride of a campestane.
Campesterol has been reported in Acanthus ilicifolius, Amaranthus hybridus, and other organisms with data available. Campesterol is a steroid derivative that is the simplest sterol, characterized by the hydroxyl group in position C-3 of the steroid skeleton, and saturated bonds throughout the sterol structure, with the exception of the 5-6 double bond in the B ring. See also: Calendula Officinalis Flower (part of); Saw Palmetto (part of). - `Campesterol` was isolated from the aerial parts of ` Chrysanthemum coronarium ` L. (crown daisy) via chromatographic methods: silica gel column chromatography (eluted with chloroform-methanol gradient) followed by preparative thin-layer chromatography (TLC) [1] - The antiangiogenic mechanism of `Campesterol` is proposed to be associated with the inhibition of vascular endothelial cell proliferation, migration, and tube formation—key steps in angiogenesis—but no specific signaling pathways (e.g., VEGF, PI3K/Akt) were verified [1] |
| 分子式 |
C₂₈H₄₈O
|
|---|---|
| 分子量 |
400.68
|
| 精确质量 |
400.37
|
| CAS号 |
474-62-4
|
| PubChem CID |
173183
|
| 外观&性状 |
White to off-white solid powder
|
| 密度 |
1.0±0.1 g/cm3
|
| 沸点 |
489.5±14.0 °C at 760 mmHg
|
| 熔点 |
156-160ºC
|
| 闪点 |
214.3±12.4 °C
|
| 蒸汽压 |
0.0±2.8 mmHg at 25°C
|
| 折射率 |
1.522
|
| LogP |
10.2
|
| tPSA |
20.23
|
| 氢键供体(HBD)数目 |
1
|
| 氢键受体(HBA)数目 |
1
|
| 可旋转键数目(RBC) |
5
|
| 重原子数目 |
29
|
| 分子复杂度/Complexity |
620
|
| 定义原子立体中心数目 |
9
|
| SMILES |
O([H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])C(C1([H])[H])=C([H])C([H])([H])[C@]1([H])[C@@]2([H])C([H])([H])C([H])([H])[C@]2(C([H])([H])[H])[C@@]([H])([C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[C@]([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])[C@]21[H]
|
| InChi Key |
SGNBVLSWZMBQTH-PODYLUTMSA-N
|
| InChi Code |
InChI=1S/C28H48O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h9,18-20,22-26,29H,7-8,10-17H2,1-6H3/t19-,20-,22+,23+,24-,25+,26+,27+,28-/m1/s1
|
| 化学名 |
(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5,6-dimethylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| 别名 |
(24R-5-Ergosten-3β-olCampesterol
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
Ethanol : ~9.09 mg/mL (~22.69 mM)
H2O : ~1 mg/mL (~2.50 mM) DMSO : ~0.67 mg/mL (~1.67 mM) |
|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: 0.91 mg/mL (2.27 mM) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 悬浮液;超声助溶。
例如,若需制备1 mL的工作液,将 100 μL 9.1 mg/mL 澄清乙醇储备液加入到 400 μL PEG300 中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 0.91 mg/mL (2.27 mM) (饱和度未知) in 10% EtOH + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 9.1 mg/mL 澄清乙醇储备液添加到 900 μL 玉米油中并充分混合。 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4958 mL | 12.4788 mL | 24.9576 mL | |
| 5 mM | 0.4992 mL | 2.4958 mL | 4.9915 mL | |
| 10 mM | 0.2496 mL | 1.2479 mL | 2.4958 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。